Enduring Hearts Inc. is a Registered 501(c)(3) Charity EIN 46-2665745
The Enduring Hearts Scientific Advisory Committee has selected the following seven research efforts with the initial funding due in May of 2016.
- Duke University Medical Center, “Prevention of homograft induced cardiac allograft vasculopathy in pediatric heart transplantation“. Total award is $249,480 (co-funded by AHA). Enduring Hearts is funding $134,719.20 in three equal installments 2016, 2017 and 2018. Lay Person Description: Chronic rejection of a heart transplant, which leads to the narrowing of the heart’s blood vessels, is a major obstacle preventing long-term survival of the organ. This research will look closely at antibodies created by the transplant recipients that is considered to have a casual effect on the development of chronic rejection.
- University of Chicago, “Reduced avidity endogenous graft-specific T cells in transplantation tolerance“. Total award is $28,080 (co-funded by AHA). Enduring Hearts is funding $15,163.20 in 2016. Lay Person Description: Transplant patients are required to be on immunosuppresive therapies to prevent organ transplant rejection. As a side effect, these therapies reduce immunity of tumors and infections.This research is to determine if certain short-term therapies could be used to target precise reactions that are responsible for organ transplant rejection without the consequence of inhibiting immunity to tumors and infections.
- University of Calgary, “Validation of a novel non-invasive assay for the detection of heart rejection“. Total award is $24,741.30, entirely funded by Enduring Hearts in 2016. Lay Person Description: This research will look at a technique of using “cell-free DNA” to detect rejection in heart transplant patients as an improvement over taking small biopsies of the heart to detect rejection that is used today.
- University of Michigan, “Decision making in adolescents and young adults pre and post heart transplantation“, Total award is $12,000 (co-funded by ISHLT). Enduring Hearts is funding $6,000 in 2016, Lay Person Description: This research will aim to characterize decision making preferences and involvement of young adults who are pre or post heart transplantation and examine associations between their decision making involvement and health-related quality of life.
- Columbia University Medical Center, “Contribution of innate-like B cells to human cardiac allograft vasculopathy“.Total award is $40,000 (co-funded by ISHLT). Enduring Hearts is funding $20,000 in 2016, Lay Person Description: This research aims to determine if B cells are the majorly contributing factor to cardiac allograft vasculopathy (CAV), the leading cause of mortality following the first year of transplantation.
- University of Illinois at Chicago,”Novel tolerogenic CD34/MSC di-chimeric cell therapy in vascularized composite allograft and heart transplant“. Total award is $174,960, entirely funded by Enduring Hearts with $87,480 in 2016. Lay Person Description: This research aims to develop a new less-toxic stem cell-based therapy, which will extend heart transplant survival without the need for life-long immunosuppression therapies (anti-rejections medication).
- Vanderbilt University, “2D speckle tracking echocardiography for non-invasive surveillance of rejection and coronary disease in pediatric heart transplant recipients“. Total award is $68,029.92, entirely funded by Enduring Hearts with $34,014.96 in 2016. Lay Person Description: This research aims to assess the ability of 2D speckle tracking to provide earlier identification of both rejection and coronary disease in pediatric heart transplant patients.